Navigation Links
Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/5/2010

available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About OFIRMEV™ (Acetaminophen) InjectionOFIRMEV (acetaminophen) injection is Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen. The FDA approval of OFIRMEV was based on data from clinical trials in which a total of 1,020 adult and 355 pediatric patients received IV acetaminophen. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever.

For more information, please see the complete OFIRMEV Prescribing Information, available at www.Ofirmev.com or www.cadencepharm.com.

Important Safety Information: OFIRMEV should be administered only as a 15 minute intravenous infusion. Do not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment.  Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The anti
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
7. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
10. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
11. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... 22, 2015  ResMed Inc. (NYSE: RMD ) today ... for the quarter was $423.0 million, a 10 percent increase ... percent increase on a constant currency basis). Net income was ... quarter ended December 31, 2013. Diluted earnings per share for ...
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical ... diabetes and obesity, announced today a new textbook,  Translational ... published by Springer, a leading global scientific publisher. ... and illustrate techniques for use in early phase clinical ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... Calif., Dec. 7, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... the company,s president and chief operating officer, is scheduled ... Annual Healthcare Conference in New York City on Wednesday, ... (Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO ) To ...
... 7, 2011   Talyst has released an updated ... The bar code technology ensures virtually 100% of medications ... The improved AutoLabel is a complete ... and white transfer labels to improve patient safety at ...
Cached Medicine Technology:Talyst Updates Its AutoLabel® Solution 2
(Date:1/22/2015)... West Hollywood, California (PRWEB) January 22, 2015 The ... 22, 2015 at 10 a.m., to commemorate the 42nd anniversary of ... the United States. , “It’s been 42 years since the Roe ... to choose is still as present as ever,” said City of ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the basic ... , Purchasing an accidental death and dismemberment rider for a ... rider provides benefits if the insured dies in an accident. ... of life insurance. , AD&D is not expensive and ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... $2 million pilot grant to fund the new ... Dartmouth. The grant is jointly funded by the ... National Institute for Environmental Health Sciences (NIEHS). Dartmouth,s ... are undertaking interdisciplinary research to assist public health ...
... ORLANDO A new drug appears to help chronic myeloid ... and second-line drugs have failed them or because their cancer ... start, researchers reported at the 52nd Annual Meeting of the ... trial, the drug ponatinib produced major or complete hematologic responses ...
... from four innovative studies help answer outstanding questions about ... Research will be presented today at the 52nd Annual ... there is no increase in overall cancer risk in ... of a double cord blood stem cell transplant is ...
... blood transfusions combined with daily medication to remove the ... the risk of recurrent strokes in young patients with ... a multicenter trial that includes St. Jude Children,s Research ... treatments for the potentially life-threatening problem of iron overload ...
... VanTine HealthDay Reporter , MONDAY, Dec. 6 ... school and in the court system than straight teens ... study suggests. "Our analysis found that, consistently, ... of being punished by school and criminal-justice authorities than ...
... Amanda Gardner HealthDay Reporter , SUNDAY, Dec. ... report that they managed to "correct" a malfunctioning gene ... disorder that leads to prolonged bleeding from even minor ... to certain cancers and dangerous infections. However, one ...
Cached Medicine News:Health News:Dartmouth receives $2 million grant for children's health research center 2Health News:Phase I trial indicates ponatinib may thwart most resistant CML 2Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 2Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 3Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 4Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 5Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 6Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 7Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 8Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 9Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 10Health News:2 studies provide insight into stroke risk and prevention in young sickle cell anemia patients 2Health News:2 studies provide insight into stroke risk and prevention in young sickle cell anemia patients 3Health News:Gay Teens Punished More Harshly Than Straight Peers: Analysis 2Health News:Gay Teens Punished More Harshly Than Straight Peers: Analysis 3Health News:Gene Therapy Corrected Rare Bleeding Disorder: Study 2Health News:Gene Therapy Corrected Rare Bleeding Disorder: Study 3
Phacoemulsification system is a complete anterior segment surgical instrument. Its simplified design and unique innovations provide optimal surgical performance....
Aaron Burr II with disposable 1mm burr for corneal rust ring removal and a diamond burr tip for polishing the pterygium bed after surgical removal and for lid margin lesions....
Algerbrush II corneal rust ring remover battery powered...
Non-Illuminated Trial Lens Set with lenses mounted in plastic frames....
Medicine Products: